Projects per year
Projects
Search results
-
Active
Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (POST-PV/ET MF)
Perkins, A. & Kennedy, N.
5/05/21 → 31/12/24
Project: Research
-
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/ul).
Perkins, A., Ma, C. K. K. & Kennedy, N.
16/03/21 → 31/12/26
Project: Research
-
A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Perkins, A. & Kennedy, N.
4/03/21 → 31/12/26
Project: Research
-
Gene editing to cure sickle cell disease
National Health and Medical Research Council (NHMRC) (Australia)
1/01/21 → 31/12/24
Project: Research
-
A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2).
Perkins, A., Kennedy, N., Hamad, N., Chuah, H., Arbelaez, A. & Prasad, R.
12/10/20 → 31/12/25
Project: Research
-
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy
Perkins, A., Leahy, M. F., Ross, D., Prasad, R., Kennedy, N. & Choi, P.
5/02/20 → 31/12/25
Project: Research
-
An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post-PV-MF), Or Post–Essential Thrombocythemia MF(Post–ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor (KRT-232-101)
Perkins, A. & Kennedy, N.
20/01/20 → 31/12/25
Project: Research
-
A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera (KRT-232-102)
Perkins, A., Burbury, K. L. & Kennedy, N.
20/01/20 → 31/12/25
Project: Research
-
Validation of new druggable JAK-STAT targets in myeloproliferative neoplasms
1/01/20 → 31/12/22
Project: Research
-
Development of Improved Biomarkers and Targeted Therapies for Myeloproliferative Neoplasms
Perkins, A. & Butler, L. A.
1/01/20 → 27/10/22
Project: Research
-
A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of Fedratinib compared to best available therapy in subjects with DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and previously treated with ruxolitinib (The FREEDOM 2 trial)
Perkins, A. & Kennedy, N.
16/12/19 → 31/12/25
Project: Research
-
A randomized, open-label, phase I/II open platform study evaluating safety and efficacy of novel ruxolitinib combinations in myelofibrosis patients.
Perkins, A. & Kennedy, N.
23/08/19 → 31/12/24
Project: Research
-
Improving survival in myelofibrosis
Perkins, A., Ross, D., Lane, S., Forsyth, C. J., Wei, A., Curtis, D., Shortt, J., Erber, W. N. & Stevenson, W. S.
Department of Health (Australia)
3/01/19 → 31/12/23
Project: Research